Neogen® Introduces Igenity® BCHF to Help Industry Mitigate Bovine Congestive Heart Failure Riskf
January 21, 2025
Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food security solutions, announced today the launch of Igenity® BCHF to improve overall bovine heart health standards. Neogen Corporation (PRNewsfoto/Neogen Corporation) Bovine Congestive Heart Failure (BCHF) stands as a significant threat to cattle health and productivity, and this genomic test provides a new opportunity for...
Novo Nordisk A/S – share repurchase programme
January 20, 2025
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part...
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
January 16, 2025
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLOTM (tabelecleucel) Biologics...
Azitra Announces Proposed Public Offering of Common StockAzitra Announces Proposed Public Offering of Common Stock
January 15, 2025
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has commenced a public offering of shares of its common stock (or pre-funded warrants in lieu thereof). All of the shares of common stock (or pre-funded warrants in lieu thereof)...
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
January 14, 2025
Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year. The company also shared 2025 revenue guidance, anticipating sales will be between $58.0 billion and $61.0 billion. For Q4 2024, Lilly now expects worldwide revenue...
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
January 13, 2025
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and...
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand
January 9, 2025
Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today posted an investor presentation in connection with its pending transaction with GHO Capital...
Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease
January 8, 2025
Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being investigated to treat patients with early Alzheimer’s disease (AD) in the Phase 2b “AuTonomy” study. The internally discovered mAb has shown the potential in...
Teladoc Health to Participate in Upcoming Investor Conferencev
January 7, 2025
Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Chuck Divita, chief executive officer, and Mala Murthy, chief financial officer, will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4:30 p.m. PT (7:30 p.m. ET)....
XORTX Adds Late Stage Gout Program to Pipeline
January 6, 2025
XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026...